<?xml version="1.0" encoding="UTF-8"?>
<!-- DDI-MAJOR-005: Clopidogrel + IBP (Omeprazol) - Reducao Eficacia Antiagregante -->
<definitions xmlns="https://www.omg.org/spec/DMN/20191111/MODEL/" id="DDI_MAJOR_005" name="DDI-MAJOR-005: Clopidogrel + IBP" namespace="http://camunda.org/schema/1.0/dmn">
  <decision id="ddi_major_005_decision" name="Clopidogrel + Omeprazol - Reducao Antiagregacao">
    <decisionTable id="ddi_major_005_table" hitPolicy="FIRST">
      <input id="input_medicamentos_ativos"><inputExpression typeRef="string"><text>medicamentosAtivos</text></inputExpression></input>
      <input id="input_medicamento_novo"><inputExpression typeRef="string"><text>medicamentoNovo</text></inputExpression></input>
      <output id="output_nivel_alerta" name="nivelAlerta" typeRef="string"><outputValues><text>"Alerta","Atencao","Informativo","OK"</text></outputValues></output>
      <output id="output_acao_requerida" name="acaoRequerida" typeRef="string" />
      <output id="output_justificativa" name="justificativaCientifica" typeRef="string" />

      <rule id="rule_clopidogrel_omeprazol">
        <inputEntry><text>list contains(medicamentosAtivos, "CLOPIDOGREL")</text></inputEntry>
        <inputEntry><text>"OMEPRAZOL" or "ESOMEPRAZOL"</text></inputEntry>
        <outputEntry><text>"Atencao"</text></outputEntry>
        <outputEntry><text>"FDA alerta: Omeprazol/esomeprazol inibem CYP2C19, reduzindo conversao de clopidogrel em metabolito ativo (~40%). Preferir pantoprazol ou lansoprazol (menor interacao). Se IBP indispensavel por alto risco GI, considerar ticagrelor ou prasugrel."</text></outputEntry>
        <outputEntry><text>"FDA Drug Safety Communication 2010. Controversia clinica, mas cautela recomendada em alto risco CV."</text></outputEntry>
      </rule>
      <rule id="rule_clopidogrel_pantoprazol">
        <inputEntry><text>list contains(medicamentosAtivos, "CLOPIDOGREL")</text></inputEntry>
        <inputEntry><text>"PANTOPRAZOL" or "LANSOPRAZOL" or "RABEPRAZOL"</text></inputEntry>
        <outputEntry><text>"Informativo"</text></outputEntry>
        <outputEntry><text>"Pantoprazol/lansoprazol tem menor inibicao CYP2C19 que omeprazol. Combinacao mais segura. Manter se protecao gastrica necessaria."</text></outputEntry>
        <outputEntry><text>"Pantoprazol preferido por menor interacao CYP2C19. Siller-Matula JM, Eur Heart J 2009."</text></outputEntry>
      </rule>
      <rule id="Rule_Fallback">
        <inputEntry><text>-</text></inputEntry>
        <inputEntry><text>-</text></inputEntry>
        <outputEntry><text>"OK"</text></outputEntry>
        <outputEntry><text>""</text></outputEntry>
        <outputEntry><text>""</text></outputEntry>
      </rule>
    </decisionTable>
  </decision>
</definitions>
